Drug intelligence / Profile preview

bromhexine + chlorpheniramine + dextromethorphan + guaifenesin + menthol

Development stage
Unknown
Lead developer
Minova Life Sciences
Modality
Small Molecules
Administration
Oral
01

Overview

Vizcof Linctus is an oral combination syrup developed by Minova Life Sciences for the treatment of productive cough, chest congestion, and respiratory symptoms associated with conditions such as bronchitis, bronchial asthma, and allergies. It contains five active ingredients: bromhexine (a mucolytic that thins and loosens phlegm), guaifenesin (an expectorant that increases airway fluid volume to facilitate mucus clearance), dextromethorphan (a centrally acting antitussive that suppresses the cough reflex), chlorpheniramine (an antihistamine that relieves allergy-related symptoms), and menthol (a cooling agent that soothes minor throat irritation). Together, these components provide a comprehensive approach to easing breathing and relieving cough discomfort.

Brand names
Vizcof LinctusVizcof Linctus SYP
02

Targets

NMDAR (Glutamate receptor ionotropic, NMDA)TRPM8 (Transient receptor potential cation channel subfamily M member 8)SIGMAR1 (Sigma non-opioid intracellular receptor 1)HRH1 (Histamine H1 Receptor)

Beyond the preview

Go deeper on bromhexine + chlorpheniramine + dextromethorphan + guaifenesin + menthol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on bromhexine + chlorpheniramine + dextromethorphan + guaifenesin + menthol.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call